Nrx Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
NRX Pharmaceuticals' Chairman and Chief Scientist, Jonathan C. Javitt, was granted 125,000 stock options with an exercise price of $1.7297.
NASDAQ
NRX Pharmaceuticals Director Dennis McBride was granted 25,000 stock options with an exercise price of $1.7297, vesting on April 9, 2026.
NASDAQ
NRX Pharmaceuticals Director Chaim Hurvitz was granted 25,000 stock options with an exercise price of $1.7297, vesting in April 2026.
NASDAQ
NRX Pharmaceuticals Director Patrick Flynn was granted 50,000 stock options with an exercise price of $1.7297, vesting in April 2026.
NASDAQ
Michael Abrams, CFO of NRX Pharmaceuticals, reports the acquisition of stock options.
NASDAQ
Jonathan Javitt, a director and officer of NRX Pharmaceuticals, purchased 40,000 shares of common stock at $1.17 per share on December 17, 2024.